Celltrion (KOSE:A068270) - Stock Price, News & Analysis

A068270 Stock Overview

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea.

About the company

A068270 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 17.27% per year

Earnings have grown 17.3% per year over the past 5 years

Analysts in good agreement that stock price will rise by 33.4%

Risk Analysis

No risks detected for A068270 from our risk checks.

Celltrion, Inc. Competitors

SK bioscienceLtd

KOSE:A302440

₩5.2t

Hugel

KOSDAQ:A145020

₩1.7t

Medy-Tox

KOSDAQ:A086900

₩1.5t

PharmaResearch

KOSDAQ:A214450

₩1.1t

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion
Historical stock prices
Current Share Price	₩162,600.00
52 Week High	₩184,100.00
52 Week Low	₩131,000.00
Beta	0.23
1 Month Change	8.47%
3 Month Change	10.91%
1 Year Change	-2.53%
3 Year Change	-56.40%
5 Year Change	-22.93%
Change since IPO	1,536.20%

Recent updates

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

May 05

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Mar 25

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Shareholder Returns

	A068270	KR Biotechs	KR Market
7D	-0.1%	-0.5%	0.5%
1Y	-2.5%	-6.3%	4.4%

Return vs Industry: A068270 exceeded the KR Biotechs industry which returned -6.3% over the past year.

Return vs Market: A068270 underperformed the KR Market which returned 4.4% over the past year.

Price Volatility

Is A068270's price volatile compared to industry and market?
A068270 volatility
A068270 Average Weekly Movement	4.1%
Biotechs Industry Average Movement	7.1%
Market Average Movement	5.8%
10% most volatile stocks in KR Market	12.1%
10% least volatile stocks in KR Market	2.9%

Stable Share Price: A068270 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A068270's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	n/a	Hyong-Gi Kim	https://www.celltrion.com

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial.

Celltrion, Inc. Fundamentals Summary

How do Celltrion's earnings and revenue compare to its market cap?
A068270 fundamental statistics
Market Cap	₩22.64t
Earnings (TTM)	₩603.80b
Revenue (TTM)	₩2.30t

37.4x

P/E Ratio

9.8x

P/S Ratio

Is A068270 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A068270 income statement (TTM)
Revenue	₩2.30t
Cost of Revenue	₩1.19t
Gross Profit	₩1.11t
Other Expenses	₩506.87b
Earnings	₩603.80b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	4.35k
Gross Margin	48.20%
Net Profit Margin	26.20%
Debt/Equity Ratio	19.7%

How did A068270 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

9%

Payout Ratio

Does A068270 pay a reliable dividends?

See A068270 dividend history and benchmarks

When do you need to buy A068270 by to receive an upcoming dividend?
Celltrion dividend dates
Ex Dividend Date	Dec 27 2023
Dividend Pay Date	Apr 24 2024
Days until Ex dividend	23 days
Days until Dividend pay date	142 days

Does A068270 pay a reliable dividends?

See A068270 dividend history and benchmarks

A068270 Stock Overview

Rewards

Risk Analysis

Celltrion, Inc. Competitors

KOSE:A302440

₩5.2t

KOSDAQ:A145020

₩1.7t

KOSDAQ:A086900

₩1.5t

KOSDAQ:A214450

₩1.1t

Price History & Performance

Recent News & Updates

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500

Price target raised to ₩284,353